Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Independent researchers, Dr. Franciose van Bambeke and Dr.
Additionally, Rib-X researchers will be presenting two posters on delafloxacin, one of which discusses the activity and efficacy of delafloxacin in a Phase 2 clinical trial for complicated Skin and Skin Structure Infections. The second poster session details the in vitro activity of delafloxacin against a large, worldwide panel of methicillin-resistant Staphylococcus aureus.
Details on the presentations and abstracts are as follows: Date Time Session Title Location/Poster May 16, 3:06pm - PK/PD: The novel oxazolidinone Lecture Hall 3a 2009 3:18pm Clinical radezolid (RX-1741) Relevance accumulates in THP-1 macrophages: comparative studies with linezolid and azithromycin. May 16, 3:18pm - PK/PD: Radezolid (RX-1741), a Lecture Hall 3a 2009 3:30pm Clinical novel oxazolidinone, is Relevance active against intracellular S. aureus, L. monocytogenes and L. pneumophila phagocytosed by human THP-1 macrophages. May 17, 1:30pm - Poster In vitro activity of Topic 31: New 2009 2:30pm Session 3 delafloxacin against antimicrobials methicillin-resistant against Gram- Staphylococcus aureus positives from the United States, Poster #1080 Europe and Asia. May 18, 1:30pm - Poster Results of a Phase 2 Topic 71: 2009 2:30pm Session 5 Study Comparing Two Clinical trials Doses of Delafloxacin to of antibiotics Tigecycline in Adults Poster #1794 with Complicated Skin and Skin Structure Infections
About Rib-X Pharmaceuticals, Inc.
Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. NDAs for Rib-X’s most advanced compounds, delafloxacin and radezolid, are anticipated in the 2011/2012 timeframe. The Company’s underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company’s integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X’s iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. The Company has recently completed Phase 2 trials in cSSTI with the IV form of delafloxacin, and is currently in Phase 2 trials with radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X, as an oral/IV agent for treatment of serious Gram-positive infections and community or hospital acquired pneumonias. The RX-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria and the RX-02 discovery program is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus, multidrug-resistant Streptococcus pneumoniae and S. pyogenes.
For more information on the Rib-X mission and the pipeline, please visit the Company website at www.rib-x.com.
SOURCE Rib-X Pharmaceuticals, Inc.